Windtree Therapeutics Inc (OTCMKTS:WINT) major shareholder Pharmaceutical Holdings Lee’s bought 541,667 shares of Windtree Therapeutics stock in a transaction on Wednesday, April 4th. The shares were purchased at an average price of $4.80 per share, for a total transaction of $2,600,001.60. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of WINT remained flat at $$3.35 during mid-day trading on Friday. The stock had a trading volume of 1,221 shares, compared to its average volume of 2,234. The company has a current ratio of 0.10, a quick ratio of 0.10 and a debt-to-equity ratio of -0.33. Windtree Therapeutics Inc has a 12-month low of $2.60 and a 12-month high of $33.20.
Separately, ValuEngine raised Windtree Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.